Author(s): Campbell R.; Nelson E.; Hocking J.; Hickey T.; Hodgins J.; Geraghty V.
Source: Journal of Crohn's and Colitis; Feb 2018; vol. 12
Publication Date: Feb 2018
Publication Type(s): Conference Abstract
Abstract:Background: In the current financial climate the NHS is under pressure to change medications in order to improve the cost-effectiveness of prescribing. Despite this practice being widespread, there is a paucity of information on how patients feel about these changes. A key strategy for preventing relapses in patients with inflammatory bowel disease (IBD) is treatment with Mesalazine. Anecdotal reports have suggested that IBD patients find changes in their IBD medication worrying and that this may destabilise symptom control.
Database: EMBASE
Source: Journal of Crohn's and Colitis; Feb 2018; vol. 12
Publication Date: Feb 2018
Publication Type(s): Conference Abstract
Abstract:Background: In the current financial climate the NHS is under pressure to change medications in order to improve the cost-effectiveness of prescribing. Despite this practice being widespread, there is a paucity of information on how patients feel about these changes. A key strategy for preventing relapses in patients with inflammatory bowel disease (IBD) is treatment with Mesalazine. Anecdotal reports have suggested that IBD patients find changes in their IBD medication worrying and that this may destabilise symptom control.
Database: EMBASE
RSS Feed
